Download 1- Adjuvant hypofractionated versus conventional fractionated

fractionated radiotherapy in breast Adjuvant hypofractionated versus conventional -1
.cancer
Between June 2002 and November 2003.143 patients with breast cancer operated upon by
patients) received post operative 07( 1 were enrolled.Group modified radiacal mastectomy
radiotherapy 50 Gy in 5
Computed tomograghy assessment of radiation induced lung disease and mimicking -2
.conditions
port,radiation dose and interval since therapy are essential to Knowledge about radiation
radiologically diagnose post radiation changes and to differentiate them from other radiologic
finding as rec
A Phase II Study of Outpatient Biweekly Gemcitabine/Oxaliplatin in Advanced Biliary -3
Tract Carcinomas
Objectives: Biliary tract carcinomas are uncommon but highly fatal malignancies. Unfortunately,
most cases are ineligible for surgery at diagnosis with chemotherapy being the mainstay of
treatment. Th
Preoperative concurrent chemotherapy in locally advanced rectal cancer using an -4
.oxaliplatin- containing regimen : A phase II Study
Purpose: The combination of radiation, 5-fluorouracil and oxaliplatin in locally advanced rectal
cancer has been shown to be feasible in phase 1 trials. The purpose of this phase II trial was to
asses
Phase II study of concurrent paclitaxel, cisplatin and radiotherapy as preoperative -5
.treatment for patients with resectable thoracic esophageal carcinoma
The improved survival of patients treated by preoperative multimodality therapy compared to
surgery alone had been proved by limited number of large randomized studies. The present study
supports the
Mansoura randomized trial: Irinotecan/de Gramont regimen versus de Gramont -6
.regimen alone in chemotherapy-naïve metastatic colorectal carcinoma
and survival figures of our The introduction of irinotecan significantly improved the control rate
.metastatic colorectal carcinoma cases over the de Gramont reimen
Concomitant Chemoradiotherapy Using Low-Dose Weekly Gemcitabine Versus Low- -0
Cell Carcinoma: Dose Weekly Paclitaxel in Locally Advanced Head and Neck Squamous
A phase III Study
The objective of this study was to compare concomitant chemoradiotherapy based on weekly
low-dose gemcitabine versus weekly low-dose paclitaxel in locally advanced head and neck
squamous cell carcinom
Single agent carboplatin versus combination chemotherapy in advanced ovarian -8
carcinoma:An Egyptian institute experience
The survival data of ovarian carcinoma after application of the chemotherapy regimens CAP,CP,
However, carboplatin has better toxicity profile .and Carboplatin are comparable
Conventional versus hyperfractionated radiotherapy in locally advanced head and neck -9
.cancer
hyperfractionated radiotherapy resulted in better progression- free survival but at the eexpense of
increased acute toxicity
.Intraarterial chemotherapy in elderly patients with invasive bladder cancer -17
intraarterial chemotherapy followed by radiotherapy can be an effective management for muscle
.invasive bladder carcinoma.However the results are preliminary
‫‪. .Prognostic role of matrix metalloproteinase-9 in patients with osteosarcoma -11‬‬
‫‪matrix metalloproteinase-9 in patients with osteosarcoma predicts poor survival‬‬
‫‪ -12‬سد العقدة العصبية العنقية يقوى اثر سد العصب اعلى عظم الكتف بعد ازالة الثدى‬
‫‪Stellate ganglion block in addition to suprascpular nerve block achieves satisfactory results in‬‬
‫‪managing shoulder pain post mastectomy‬‬
‫‪ -13‬دور العالج االشعاعي منخفض التجزئه في عالج سرطان الراس و العنق المتقدم موضوعيا في مرضي مسنيين‬
‫يعد العالج االشعاعي منخفض التجزئه ذو نتائج يمكن قبولها بانسبه للمرضي المسنيين الذين يعانون من سرطان راس و عنق‬
‫متقدم وذلك اذا اخذنا في االعتبار مناسبة االعراض الجانبيه الناتجه للحاله الصحيه لهؤالء المر‬
‫‪ -14‬المدلول التكهني لماده االنترليوكن ‪ 8‬في المرضي البالغين المصابين بورم الغدد اللمفاويه الغير هودجيكن‬
‫وجد انه باالضافه الي العديد من العوامل التكهنيه لتي تم اكتشافها مؤخرا في مرض االورام اللمفاويه الغير هودجيكن فانه يعتبر‬
‫االنترليوكن ‪ 8‬عامل تكهني يمكن اخذه في االعتبار عند اختيار العالج المناسب للمريض‬
‫‪ -15‬البالتينول باالضافه الي االيفوسفاميد في عالج سرطان الثدي المنتشر ثالثي السلبيه و الذي سبق عالجه باستخدام‬
‫االنثراسيكلن و التكسان ‪ :‬دراسه من المرحله الثانيه‬
‫‪Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and‬‬
‫‪.taxane-pretreated breast cancer patients;seems feasible, however phase three studies are needed‬‬
‫‪ -16‬نسبه معامل النمو ب ب الصادر من الصفائح الدمويه في مرضي سرطان الغدد اللمفاويه الغير هودجيكن‬
‫معامل النمو ب ب الصادر من الصفائح الدمويه ليس فعاال في نشأة ذلك السرطان ويؤدي العالج الكيماوي الي ارتفاع نسبته في‬
‫الدم مما يعكس النشاط التصنيعي لألوعيه الدمويه و الذي يعد عامال في مقاومة السرطان للعال‬
‫‪ -10‬عقار الميثوتريكسات و البكليتاكسل و االبيروبيسين و الكربوبالتن كخط عالج كيماوي ثاني في مرضي سرطان الخليه‬
‫التحوريه بالمثانه و المنتشر‬
‫البروتوكول المكون من الميثوتريكسات والباكليتاكسيل واألبيروبسين والكاربوبالتين حقق بعض النتائج األيجابية من حيث‬
‫األستجابة ومعدالت التسمم ولكن المزيد من الدراسات الزال مطلوبا لتحسين تلك النتائج‬
‫‪Biweekly peglated liposomal doxorubicin / oxaliplatin for ovarian cancer resistant to -18‬‬
‫‪taxane-platinum treatment: a phase II study‬‬
‫‪Aim: The aim of this phase II study was to evaluate the activity and safety of biweekly pegylated‬‬
‫‪liposomal doxorubicin (PLD) and oxaliplatin (L-OHP) in patients with platinum-taxene resistant‬‬
‫‪ovarian‬‬
‫‪Irinotecan plus Cisplatin Chemotherapy Followed By Concurrent Throracic -19‬‬
‫‪For Limited- Disease Small-Cell Lung Irradiation With Low-Dose Weekly Cisplatin‬‬
‫‪Cancer‬‬
‫‪Back ground: A phase II trial of irinotecan and cisplatin (IP) as induction chemotherapy followed‬‬
‫‪by conventional thoracic irradiation concurrent with low-dose weekly cisplatin for limited‬‬‫‪disease sma‬‬